Targeting protein tyrosine kinase 6 enhances apoptosis of colon cancer cells following DNA damage

Molecular Cancer Therapeutics

Volumn 11, Issue 11, 2012, Pages 2311-2320

  Gierut, Jessica J ^a   Mathur, Priya S ^a   Bie, Wenjun ^a   Han, Jin ^a   Tyner, Angela L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; P21 ACTIVATED KINASE; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 6; SHORT HAIRPIN RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL STRAIN HCT116; CELL SURVIVAL; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; DNA DAMAGE; GAMMA RADIATION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROCESSING; PROTEIN TARGETING; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; COLONIC NEOPLASMS; DNA DAMAGE; GAMMA RAYS; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HUMANS; MICE; NEOPLASM PROTEINS; PROTEIN-TYROSINE KINASES; RECOMBINANT PROTEINS; STAT3 TRANSCRIPTION FACTOR;

EID: 84869208687     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0009     Document Type: Article

References (49)

1. Brauer PM, Tyner AL. Building a better understanding of the intracellular tyrosine kinase PTK6-BRK by BRK. Biochim Biophys Acta 2010;1806:66-73.
2. Ostrander JH, Daniel AR, Lange CA. Brk/PTK6 signaling in normal and cancer cell models. Curr Opin Pharmacol 2010;10:662-9.
3. Siyanova EY, Serfas MS, Mazo IA, Tyner AL. Tyrosine kinase gene expression in the mouse small intestine. Oncogene 1994;9:2053-7. (Pubitemid 24194173)
4. Vasioukhin V, Serfas MS, Siyanova EY, Polonskaia M, Costigan VJ, Liu B, et al. A novel intracellular epithelial cell tyrosine kinase is expressed in the skin and gastrointestinal tract. Oncogene 1995;10:349-57.
5. Llor X, Serfas MS, Bie W, Vasioukhin V, Polonskaia M, Derry J, et al. BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res 1999;5:1767-77. (Pubitemid 29334458)
6. Derry JJ, Prins GS, Ray V, Tyner AL. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene 2003;22:4212-20. (Pubitemid 36876242)
7. Haegebarth A, Bie W, Yang R, Crawford SE, Vasioukhin V, Fuchs E, et al. Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine. Mol Cell Biol 2006;26:4949-57. (Pubitemid 43955811)
8. Palka-Hamblin HL, Gierut JJ, Bie W, Brauer PM, Zheng Y, Asara JM, et al. Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6. J Cell Sci 2010;123:236-45.
9. Haegebarth A, Perekatt AO, Bie W, Gierut JJ, Tyner AL. Induction of protein tyrosine kinase 6 in mouse intestinal crypt epithelial cells promotes DNA damage-induced apoptosis. Gastroenterology 2009;137:945-54.
10. Gierut J, Zheng Y, Bie W, Carroll RE, Ball-Kell S, Haegebarth A, et al. Disruption of the mouse protein tyrosine kinase 6 gene prevents STAT3 activation and confers resistance to azoxymethane. Gastroenterology 2011;141:1371-80. e2.
11. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011;6:479-507.
12. Clarke AR, Gledhill S, Hoper ML, Bird CC, Wyllie AH. p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 1994;9:1767-73. (Pubitemid 24163407)
13. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, et al. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 1994;54:614-7. (Pubitemid 24068309)
14. 2/M-associated cell death after gamma-irradiation. Oncogene 1997;14:2759-66.
15. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-49.
16. Gudkov AV, Komarova EA. Pathologies associated with the p53 response. Cold Spring Harb Perspect Biol 2010;2:a001180.
17. Kirsch DG, Santiago PM, di Tomaso E, Sullivan JM, Hou WS, Dayton T, et al. p53 controls radiation-induced gastrointestinal syndromein mice independent of apoptosis. Science 2010;327:593-6.
18. 1 arrest in human cancer cells. Cancer Res 1995;55:5187-90.
19. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents [see comments]. J Clin Invest 1999;104:263-9.
20. Whitehead RH, Robinson PS. Establishment of conditionally immortalized epithelial cell lines from the intestinal tissue of adult normal and transgenic mice. Am J Physiol Gastrointestinal Liver Physiol 2009;296:G455-60.
21. Whitehead RH, Robinson PS, Williams JA, Bie W, Tyner AL, Franklin JL. Conditionally immortalized colonic epithelial cell line from a Ptk6 null mouse that polarizes and differentiates in vitro. J Gastroenterol Hepatol 2008;23:1119-24. (Pubitemid 352019378)
22. Brauer PM, Zheng Y, Evans MD, Dominguez-Brauer C, Peehl DM, Tyner AL. The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of beta-catenin. PLoS ONE 2011;6:e14789.
23. Rasband WS. ImageJ. Bethesda (MD): U S National Institutes of Health; 1997-2011. Available at: http://imagej.nih.gov/ij/. Accessed 2011-2012.
24. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501. (Pubitemid 28538613)
25. 1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
26. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992;19:670-86. (Pubitemid 23004844)
27. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8. (Pubitemid 37328853)
28. Macleod K, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995;9:935-44.
29. Wang X, Tournier C. Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal 2006;18:753-60. (Pubitemid 43208930)
30. Castro NE, Lange CA. Breast tumor kinase and extracellular-signal- regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast Cancer Res 2010;12:R60.
31. Locatelli A, Lofgren KA, Daniel AR, Castro NE, Lange CA. Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression. Horm Cancer 2012;3:14-25.
32. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-13.
33. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009;15:91-102.
34. Liu L, Gao Y, Qiu H, Miller WT, Poli V, Reich NC. Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene 2006;25:4904-12. (Pubitemid 44201181)
35. Haegebarth A, Heap D, Bie W, Derry JJ, Richard S, Tyner AL. The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2. J Biol Chem 2004;279:54398-404. (Pubitemid 40053179)
36. Kim HI, Lee ST. Oncogenic functions of PTK6 are enhanced by its targeting to plasma membrane but abolished by its targeting to nucleus. J Biochem 2009;146:133-9.
37. Brauer PM, Zheng Y, Wang L, Tyner AL. Cytoplasmic retention of protein tyrosine kinase 6 promotes growth of prostate tumor cells. Cell Cycle 2010;9:4190-9.
38. Zheng Y, Gierut J, Wang Z, Miao J, Asara JM, Tyner AL. Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT. Oncogene 2011;300:C657-70.
39. Zheng Y, Asara JM, Tyner AL. Protein-tyrosine kinase 6 promotes peripheral adhesion complex formation and cell migration by phosphorylating p130 CRK-associated substrate. J Biol Chem 2012;287:148-58.
40. Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, et al. PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS ONE 2010;5:e11729.
41. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137:413-31.
42. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. The J Cell Biol 2011;192:209-18.
43. Gartel AL, Serfas MS, Gartel M, Goufman E, Wu GS, El-Deiry WS, et al. p21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelial and during differentiation of the Caco-2 intestinal cell line. Exp Cell Res 1996;227:171-81. (Pubitemid 26320157)
44. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9:400-14.
45. Komarova EA, Kondratov RV, Wang K, Christov K, Golovkina TV, Goldblum JR, et al. Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 2004;23:3265-71. (Pubitemid 38669816)
46. Leibowitz BJ, Qiu W, Liu H, Cheng T, Zhang L, Yu J. Uncoupling p53 functions in radiation-induced intestinal damage via PUMA and p21. Mol Cancer Res 2011;9:616-25.
47. Ravizza R, Gariboldi MB, Passarelli L, Monti E. Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin. BMC Cancer 2004;4:92.
48. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
49. Matthews JR, Sansom OJ, Clarke AR. Absolute requirement for STAT3 function in small-intestine crypt stem cell survival. Cell death and differentiation 2011;18:1934-43.